Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. - Wikidata - awgldk - TriplyDB

Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.

Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.

http://www.wikidata.org/entity/Q37227687

about

Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) - From Preclinical Studies to a Clinical Phase II Trial Positron emission tomography/computerized tomography in lung cancer.Absence of a relationship between tumor ¹⁸F-fluorodeoxyglucose standardized uptake value and survival in patients treated with definitive radiotherapy for non-small-cell lung cancer Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2'-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles.Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review.Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer.Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235.Metabolic response assessment with (18)F-FDG PET/CT: inter-method comparison and prognostic significance for patients with non-small cell lung cancer.Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.Which variables should be considered in patients with stage II and III non-small cell lung cancer after neoadjuvant therapy?The Globalization of Cooperative Groups.Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235 Stage III Non-Small Cell Lung Cancer: Prognostic Value of FDG PET Quantitative Imaging Features Combined with Clinical Prognostic Factors Pretreatment 18F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235.Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB-IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities.An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept study.Monitoring and management of lung cancer patients following curative-intent treatment: clinical utility of 2-deoxy-2-[fluorine-18]fluoro-d-glucose positron emission tomography/computed tomography.Developing biomarker-specific end points in lung cancer clinical trials.Image-derived biomarkers and multimodal imaging strategies for lung cancer management.IBEX: an open infrastructure software platform to facilitate collaborative work in radiomics.PET in the management of locally advanced and metastatic NSCLC.Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.Early-Stage Non-Small Cell Lung Cancer: Quantitative Imaging Characteristics of (18)F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis.Present and future roles of FDG-PET/CT imaging in the management of lung cancer.Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot Study Prognostic value of the standardized uptake value maximum change calculated by dual-time-point (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer.Prognositc significance of SUVmax on pretreatment 18 F-FDG PET/CT in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy: A meta-analysis.Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer.Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235.Molecular Tools for Facilitative Carbohydrate Transporters (Gluts).Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review.Watch the weathercock: changes in re-staging 18F-FDG PET/CT scan predict the probability of relapse in locally advanced non-small cell lung cancer.Reduction in Tumor Volume by Cone Beam Computed Tomography Predicts Overall Survival in Non-Small Cell Lung Cancer Treated With Chemoradiation Therapy.Impact of total lesion glycolysis measured by (18)F-FDG-PET/CT on overall survival and distant metastasis in hypopharyngeal cancer.Can radiomics features be reproducibly measured from CBCT images for patients with non-small cell lung cancer?Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

P2860

Q26771327-D972C529-75CD-4E4F-A690-66F3A58CB2F3 Q26858884-22D0E21B-729D-4C8C-B70A-C2E7672A314E Q33657999-A34248E1-5716-496C-A20C-8009D4AB889A Q34041796-12423524-E775-4D79-8488-DAE49A1AAC64 Q34289406-163371EE-EC64-4C62-ACFC-A4737F7F418F Q34667302-E800B5D6-43AD-41CE-924F-A1FBDACB04D6 Q34695293-6D28A86F-1610-438A-9360-E8929F3669CF Q35146660-701F0A59-AADB-4998-85A5-FD7AB7CDF77C Q35474006-3CFD2FE3-B591-45A0-B2A0-7D3623B51D2E Q36024114-C7006F0C-6FC0-4E72-B9F4-9C9C24F14990 Q36056706-1107BD8C-0A42-402A-B4F9-09FA323C5C91 Q36071492-3D5EF1EC-CAD2-4411-BE82-5C9EFAE9A2AD Q36119749-0BB3398C-7761-4EE4-9D43-513217F2BA29 Q36288418-74F37269-D765-42E2-9C1F-BA92608353E2 Q36425348-4EDF5BAA-1A36-4373-8272-2709BE466D50 Q37180546-E66B8E81-0AE9-4084-8016-6037619C0E29 Q37261280-B437D5DE-5A2D-4BF9-AFA9-F8472C420730 Q37567299-56B89141-CD97-4C52-A941-F4038C0E2515 Q37601150-44AF305B-337F-4C64-BC4F-5599AC4C5C64 Q37643555-90718CAE-F62B-41EF-BAA6-C38E9F2B4716 Q38297892-0ABCC10C-9E13-408A-A711-4A7E0C36A55E Q38312373-09F7E5C4-7DBF-4182-9034-D7C3A64AC231 Q38367229-E05FAAE9-27ED-4AB9-BD93-A86A5AEC54D3 Q38444980-6BC7A84A-F62A-4737-801F-7C0C8DFBDA34 Q38660859-70B03154-40F8-436C-A97E-EBEE3373C415 Q38798562-0D48577F-7270-4E78-9D44-95CBF031F46D Q38819166-EC767D8D-BDA7-48EB-BDE6-87E0D865B206 Q38841400-42A781E1-866F-4E94-8B2D-CC23E6B9B9A8 Q38860955-08D1ED80-EDA7-4611-AE56-239902208E1F Q38925620-3B0753D7-3BD5-4EC7-B43E-494921A5F697 Q39135164-A5DB46F2-5D33-41A4-BF48-15FEF35E0DCD Q39373649-1A9ED978-C442-4266-817B-368553BEF68A Q39388237-63FFEC53-50BE-40AB-A915-83900E6AB298 Q39417217-BC2A9500-F158-4FD8-8569-5AC0238327D9 Q41555630-5C88AE8A-1E9B-4DF0-85E2-89139F89372D Q41675808-4EA2D35F-A573-4660-8BD0-FF3B2A1EDE60 Q41777552-1AAD8A10-BE77-4AD9-9E4A-84A5091AD324 Q41994050-440E6601-B6D2-4188-A97F-7DC8D3B99834 Q47718840-BD4D9EA8-11A2-438F-8CDB-71D22AE99F01 Q47777467-03C5E059-1B4D-49B6-9BFE-2A34AE32A049

P2860

Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.

http://www.wikidata.org/entity/Q37227687

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Prediction of survival by [18F ...... he ACRIN 6668/RTOG 0235 trial.

@en

Prediction of survival by [18F ...... he ACRIN 6668/RTOG 0235 trial.

@nl

type

label

Prediction of survival by [18F ...... he ACRIN 6668/RTOG 0235 trial.

@en

Prediction of survival by [18F ...... he ACRIN 6668/RTOG 0235 trial.

@nl

prefLabel

Prediction of survival by [18F ...... he ACRIN 6668/RTOG 0235 trial.

@en

Prediction of survival by [18F ...... he ACRIN 6668/RTOG 0235 trial.

@nl

P1433

Q37227687-13938ACC-71EE-4BAA-9323-1749CAD3F8D0

P1476

Q37227687-DCDBF68F-A5AE-4930-953E-1EC4301389A1

P2093

Q37227687-8900DAD5-9013-4195-AB06-12BDFF94485B

Q37227687-8F7BB3A4-C6A2-478B-9604-F9F8BCCEE058

Q37227687-A3045074-3EEF-44AF-B3D6-34F9859AB01F

Q37227687-ADF03CDD-35D7-4FA5-BAB2-ECDC6BE98B17

Q37227687-BB54054E-6228-4B08-9C62-19465C513CB6

Q37227687-BBE02207-D27C-482C-8541-44EE720F559A

Q37227687-D5D58742-F3A2-45C1-83C5-26B99DEC6C87

Q37227687-E09D55E4-8D2C-46A4-BAD4-3EC413360919

Q37227687-E85A30FE-BB26-457A-8268-23FBC33DB595

Q37227687-E97F30F3-636B-4112-B075-7A49E6AD3A86

P2860

Q37227687-00147C23-5615-4416-BA22-4C6C52A9676E

Q37227687-01367D86-1404-474F-9C29-E41085433D5B

Q37227687-09D93279-F9CA-42B8-9B81-A8E6D4BB1263

Q37227687-0D6016EC-030B-434E-B8BF-2BCA9BB61EF3

Q37227687-0F5CAA6E-3797-4389-A759-6DBECCAF0A69

Q37227687-13ADE6E3-D7DC-4FF1-AC90-8EA2859E0978

Q37227687-1940D564-F599-4FAE-B2BC-22262A8C0156

Q37227687-25F4F70D-D7F3-4F8A-AB74-C48CCCFF7515

Q37227687-4658A414-B7E6-438E-B98D-991D47AB9E19

Q37227687-549F5FA1-286B-4CD7-B5AC-77CC225C5407

P304

Q37227687-B2F4AA3C-BBF2-41DD-9BD2-11ABD1113F14

P31

Q37227687-AD125C09-0C6A-41C4-9406-C71784BCEBD1

P356

Q37227687-7C562707-99B1-44C7-B480-9EBA8A0F1052

P407

Q37227687-1943414E-675C-4932-B04E-885D7C81FA66

P433

Q37227687-AF3C7A09-1CA9-41EB-9E14-66AE59EC0633

P478

Q37227687-4E07B0C5-6BBB-49E8-9727-E6D866A0C478

P50

Q37227687-351DFE77-228C-4087-B137-525CF1F38179

Q37227687-B99D66BE-9825-4230-A213-A4F67737E520

P577

Q37227687-DC735B77-AAE2-41E7-A465-B4DE1A40A50F

P698

Q37227687-F6F13A76-B0A8-41EF-B965-D6655C7C0C5F

P921

Q37227687-46EB14F1-7897-4671-9672-6FEBBCA16A9E

Q37227687-6052BF35-6F6B-48B6-B7D5-C4CB20DA1A36

P932

Q37227687-6DD85E11-C2BC-44B1-AAD0-34F3370DEEA1

P356

JCO.2012.47.5947

P1433

Journal of Clinical Oncology

P1476

Prediction of survival by [18F ...... he ACRIN 6668/RTOG 0235 trial.

@en

P2093

Abass Alavi

http://www.w3.org/2001/XMLSchema#string

Albert DeNittis

http://www.w3.org/2001/XMLSchema#string

Barry A Siegel

http://www.w3.org/2001/XMLSchema#string

Bradley S Snyder

http://www.w3.org/2001/XMLSchema#string

Donald R Neumann

http://www.w3.org/2001/XMLSchema#string

Douglas W Johnson

http://www.w3.org/2001/XMLSchema#string

Fenghai Duan

http://www.w3.org/2001/XMLSchema#string

Gregory Videtic

http://www.w3.org/2001/XMLSchema#string

Homer Macapinlac

http://www.w3.org/2001/XMLSchema#string

Janet S Reddin

http://www.w3.org/2001/XMLSchema#string

P2860

High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy.

A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515.

Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer

Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan.

Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience.

Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Workin

Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.

Non-small-cell lung cancer.

Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.

PET scans in radiotherapy planning of lung cancer.

P304

3823-3830

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.47.5947

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Mitchell Machtay

P577

2013-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24043740

http://www.w3.org/2001/XMLSchema#string

P921

chemoradiotherapy

P932

3795891

http://www.w3.org/2001/XMLSchema#string